MARC TESSIER-LAVIGNE, PH.D. - Corporate Board Profile

REGENERON PHARMACEUTICALS, INC.

Filing Date	Source Excerpt
2016-04-26	MARC TESSIER-LAVIGNE, Ph.D., 56, has been a Director of the Company since November 2011. Dr. Tessier-Lavigne has been the President of The Rockefeller University since March 2011 and is a Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University. In February 2016, he was appointed the President of Stanford University effective September 1, 2016. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. Tessier-Lavigne is a member of the National Academy of Sciences, the National Academy of Medicine, and a fellow of the Royal Societies of the United Kingdom and Canada. Dr. Tessier-Lavigne is a member of the Board of Directors of Agios Pharmaceuticals, Inc. and Juno Therapeutics, Inc., and previously served on the board of directors of Pfizer Inc. Dr. Tessier-Lavigne's distinguished scientific and academic background, and his significant industry experience, including experience in senior scientific leadership roles at a leading biopharmaceutical company, led the board to conclude that Dr. Tessier-Lavigne should serve as a director.
2017-04-25	Dr. Tessier-Lavigne has been the President of Stanford University since September 2016. ... Compensation of Directors: Marc Tessier-Lavigne, Ph.D. 2,089,085.
2018-04-23	MARC TESSIER-LAVIGNE, Ph.D. Director since: 2011 Age: 58 Independent Scientific Society Memberships The National Academy of Sciences The National Academy of Medicine The Royal Society of London The Royal Society of Canada Dr. Tessier-Lavigne has been the President of Stanford University since September 2016. Before assuming his role at Stanford, he served as the President of The Rockefeller University and a Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University from March 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. Tessier-Lavigne is a member of the National Academy of Sciences, the National Academy of Medicine, and a fellow of the Royal Societies of London and Canada. Dr. Tessier-Lavigne is a member of the Board of Directors of Denali Therapeutics Inc., and previously served on the board of directors of Pfizer Inc., Agios Pharmaceuticals, Inc., and Juno Therapeutics, Inc. Board and Committee Membership: Board of Directors, Technology Committee. Compensation of Directors table shows $1,232,211 option awards, $65,000 fees earned in cash, and $5,000 all other compensation totaling $1,302,211.
2021-04-23	Dr. Tessier-Lavigne has been the President of Stanford University since 2016. Before assuming his role at Stanford, he served as the President of The Rockefeller University and a Carson Family Professor and head of the Laboratory of Brain Development at The Rockefeller University from 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., which he joined in 2003. He was a professor at Stanford University from 2001 to 2003 and at the University of California, San Francisco from 1991 to 2001. Dr. Tessier-Lavigne is a member of the National Academy of Sciences, the National Academy of Medicine, and a fellow of the Royal Societies of London and Canada. Dr. Tessier-Lavigne is a member of the Board of Directors of Denali Therapeutics Inc., and previously served on the board of directors of Pfizer Inc., Agios Pharmaceuticals, Inc., and Juno Therapeutics, Inc. Dr. Tessier-Lavigne's distinguished scientific and academic background, and his significant industry experience, including experience in senior scientific leadership roles at a leading biopharmaceutical company, led to the board's decision to nominate Dr. Tessier-Lavigne for reelection to the board. Board and Committee Membership—2020 Attendance: Board of Directors: 7/11 Technology Committee: 3/3 Prior Voting Results—2018: For: 94.8% Against: 5.2% Regeneron Securities Beneficially Owned as of April 13, 2021: Common Stock: 1,187 Options: 57,778 RSUs: 750
2022-04-21	Marc Tessier-Lavigne, Ph.D. Director since: 2011 Age: 62 Independent Board and Committee Membership–2021 Attendance Board of Directors: 9/9 Technology Committee Regeneron Securities Beneficially Owned: Common Stock: 1,187 Options: 24,835 RSUs: 974 Director Compensation Table: Marc Tessier-Lavigne, Ph.D. Total: 700,094